AGENCY AGREEMENTAgency Agreement • August 30th, 2010 • IntelGenx Technologies Corp. • Pharmaceutical preparations • British Columbia
We, Bolder Investment Partners, Ltd. (the “Agent”), understand that IntelGenx Technologies Corp. (the “Issuer”) proposes to sell up to 6,500,000 units (as hereinafter defined) at a price of $0.40 per Unit, and that the Issuer wishes to appoint the Agent as its sole and exclusive agent to distribute the Units to purchasers (the “Purchasers”) who are qualified to purchase such Units pursuant to the Exemptions (as defined below). The Agent is willing to accept such appointment, pursuant to the terms and conditions set forth below.
INTELGENX TECHNOLOGIES CORP. REGISTRATION RIGHTS AGREEMENTIntelgenx Technologies Corp. Registration Rights Agreement • August 30th, 2010 • IntelGenx Technologies Corp. • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of the º day of August, 2010 between IntelGenx Technologies Corp., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SUBSCRIPTION AGREEMENT – UNITS INTELGENX TECHNOLOGIES CORP. AND BOLDER INVESTMENT PARTNERS, LTD.Registration Rights Agreement • August 30th, 2010 • IntelGenx Technologies Corp. • Pharmaceutical preparations • Delaware
Private Placement of up to 6,250,000 units (“Units”) at $0.40 per Unit. Each unit will consist of one common share and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one common share of IntelGenx Technologies Corp. for 36 months following the closing of the offering at an exercise price of $0.50. Unless otherwise indicated, all dollar amounts referred to herein, including the symbol “$”, are in lawful currency of Canada.
